CTLA 4 News and Research

RSS

Immunotherapy response in patients with advanced melanoma depends on prior treatments

Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy – CTLA-4 blockade – as well as other factors.

10 Apr 2023

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

Ipsilateral vaccination improves response to second dose of COVID-19 vaccine

Researchers examine whether the involvement of the ipsilateral or contralateral lymph nodes affected the immune response during sequential vaccination.

16 Mar 2023

Trial shows encouraging results for neoadjuvant dual immunotherapy and chemotherapy in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

16 Mar 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

Novel triple immunotherapy combination improves anti-tumor responses in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis and limited treatment options.

3 Jan 2023

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

An experimental therapy showed promise as treatment for an aggressively spreading type of colorectal cancer in preclinical models, according to a new study by Weill Cornell Medicine investigators.

16 Dec 2022

Study: No significant difference in cancer risk in rheumatology patients with history of malignancy taking DMARDs

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, found no significant difference in cancer risk in patients with rheumatic disease and a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.

8 Nov 2022

Pioneering gene editing technique can repair faulty T cells in patients with CTLA-4 insufficiency

A fault in cells that form a key part of the immune system can be repaired with a pioneering gene editing technique, finds new research demonstrated in human cells and mice, led by UCL scientists.

27 Oct 2022

Study explores the effect of age-associated B cells on COVID-19 vaccine-induced immunity

In a new study, a team of researchers explored the effect of immune checkpoint blockade (ICB)-induced expansion of age-associated B cells (ABCs) on COVID-19 vaccine-derived humoral immunity in patients with cancer and inborn errors of immunity (IEI).

22 Sep 2022

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

Scientists explore associations between SARS-CoV-2 neutralizing antibodies and receptor-binding domain-selective proliferative memory CD4 T cells

Researchers depicted the correlations between receptor-binding domain (RBD)-selective proliferative memory CD4 T cells and neutralizing antibodies in COVID-19 vaccinees and convalescent patients.

27 Jul 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Researchers create a comprehensive map of how complex networks of genes function together

Using new technologies to study thousands of genes simultaneously within immune cells, researchers at Gladstone Institutes, UC San Francisco (UCSF), and Stanford School of Medicine have created the most detailed map yet of how complex networks of genes function together.

11 Jul 2022

Study illustrates how the use of whole exome sequencing can better predict treatment response

Immunotherapies, such as immune checkpoint inhibitors, have transformed the treatment of advanced stage cancers.

8 Jul 2022

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says

Cancer patients have received priority status to receive COVID-19 vaccinations but there is limited data regarding the safety and efficacy of the vaccines for patients treated for lung cancer with immune checkpoint inhibitors.

22 Jun 2022

How specific comorbidities impact severity of COVID-19

Researchers identify the association between severe COVID-19 and specific comorbidities.

20 Jun 2022

Targeting interleukin-6 could help reduce immune-related adverse events from immunotherapy

Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).

9 May 2022

Discovery provides critical clues to why many immunotherapies trigger dangerous side effects

It's not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.

5 May 2022